Keros Therapeutics Inc is a biotechnology company focused on developing innovative therapies to treat rare hematological and muscle disorders
The company is dedicated to advancing its proprietary drug candidates that target the transforming growth factor beta (TGF-β) superfamily, which plays a critical role in various cellular processes, including muscle and blood formation. By leveraging their expertise in molecular biology and drug development, Keros Therapeutics aims to provide new treatment options for patients with unmet medical needs while fostering advancements in the understanding of these complex diseases.
NEW YORK, Jan. 24, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Keros Therapeutics, Inc. (“Keros” or the “Company”) (NASDAQKROS) on behalf of Keros stockholders. Our investigation concerns whether Keros has violated the federal securities laws and/or engaged in other unlawful business practices.
The law firm of Kirby McInerney LLP is investigating potential claims against Keros Therapeutics, Inc. (“Keros” or the “Company”) (NASDAQKROS). The investigation concerns whether Keros and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.
The company’s stock declined nearly 60% in 2024 and has lost an additional 21% in 2025, with this latest setback further dampening investor confidence.
NEW YORK, NY / ACCESSWIRE / December 17, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros Therapeutics, Inc. ("Keros Therapeutics, Inc.") (NASDAQKROS) concerning possible violations of federal securities laws.
NEW YORK, NY / ACCESSWIRE / December 16, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros Therapeutics, Inc. ("Keros Therapeutics, Inc.") (NASDAQKROS) concerning possible violations of federal securities laws.
NEW YORK, NY / ACCESSWIRE / December 16, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Keros Therapeutics, Inc. ("Keros Therapeutics, Inc.") (NASDAQKROS) concerning possible violations of federal securities laws.
Keros Therapeutics is advancing novel therapies for hematological and cardiopulmonary disorders via TGF-β signaling regulation. Oppenheimer rates KROS Outperform with a $102 price target.
